Claims

1. Use of an inhibitor of Colony Stimulating Factor 1 (CSF-1R) activity in the manufacture of a medicament for the treatment and/or prophylaxis of idiopathic pulmonary fibrosis (IPF), wherein the inhibitor is an antibody or functionally active fragment or derivative thereof.
2. The use according to claim 1, wherein the antibody or fragment thereof is monoclonal, polyclonal, chimeric, humanised or bispecific.
3. The use according to claim 1 or claim 2, wherein the antibody fragment is a Fab, Fab', $F(ab')_2$, scFv or an epitope-binding fragment thereof.
4. The use according to any one of claims 1-3, wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).
5. The use according to any one of claims 1-4, wherein the antibody or fragment thereof binds to CSF-1R.